Seeking Alpha
View as an RSS Feed

Value Doc  

View Value Doc's Comments BY TICKER:
Latest  |  Highest rated
  • Signs Of A Stock Market Correction Developing [View article]
    On the subject of chart patterns, if you pull up a two-year chart, this year's choppy side-ways action looks identical to last year's action--this "triangle pattern" stuff is voodoo nonsense, and the "channel" stuff would have incorrectly suggested a pending correction in late 2012--just the time to get aggressively long. I say the next big move is up, not down. A big summer rally is on the way, and I suspect that it will persist right through year-end much like in 2013.

    John Burbank of Passport Capital was on Bloomberg on Thursday noting that the recent stock market softness / choppiness connected to the bond sell-off is likely a wave of forced liquidation from the big risk parity funds who have to lighten up their VAR. PIMCO out today thinks it's almost over, and Gundlach also doesn't think rates rise too much.

    That makes sense to me--we have a global reflationary industrial rebound just starting, and a market that's been flat all year--not a set-up for any type of stock correction. If the taper tantrum (much bigger back-up in rates) couldn't cause a stock correction and in fact devolved into a big stock rally, this recent back-up in rates certainly won't either.

    Best way to play the rebound is through industrials (which have been flat and mildly out-of-favor for a year and trade at 2-3 turns lower than the S&P)--try XLI and RGI.
    May 12, 2015. 10:20 PM | 2 Likes Like |Link to Comment
  • Signs Of A Stock Market Correction Developing [View article]

    I'm curious, as your article focuses on "technicals" why you don't discuss things like market internals, breadth, new highs/lows, etc.--these are cited by other prognosticators like Hussman as technical evidence of market deterioration. I would say that there's also a bit more substance to them than the chart pattern stuff you've dredged up.

    On the chart patterns, two ways to skin a cat--we keep testing this 2117 area on the S&P--if we pierce it next week, could very well lead to a breakout-driven melt-up.
    May 9, 2015. 08:42 PM | 1 Like Like |Link to Comment
  • Signs Of A Stock Market Correction Developing [View article]
    Well, the window is closing fast, and it seems very unlikely from my perch absent a Grexit or an exceedingly disorderly move in the bond markets. I also don't think the "earnings recession" (which is mostly oil sector, and note the mild decline in other sectors is likely to be reversed in the 2nd half with better growth and weaker dollar) will be strong enough to hurt stock prices--note it had no effect this past quarter.

    I would say the correction risk is actually lower than normal as the markets have gone nowhere all year, and early leading indicators clearly suggest a global rebound. The risk would be higher than normal if we had just experienced a strong rally to start the year, particularly if coupled with signs of slowing economic activity and widening junk spreads (e.g. early last summer would have been a good time to flag this warning, as would spring/summer of 2011 after ECRI flagged that global industrial growth cycle peaked in April).

    Note that bond yields have only started to rise--historically, we're not primed for a correction until the bond yields have topped out and moved sideways for several months (to give the tightening effect of the higher rates enough time exercise its choke collar effect on the economy and markets).

    Also, your assertion on an econ acceleration was way too early; it really didn't become apparent before March/April. It could have gone the other way too.
    May 9, 2015. 08:35 PM | Likes Like |Link to Comment
  • Signs Of A Stock Market Correction Developing [View article]

    Recent fundamental developments no longer support the call for a correction this year (though I would have agreed with it earlier in the year). Namely, we're on the cusp of a global industrial upturn (note recent ECRI call) with yield curves steepening all over the world, junk spreads tightening, commodities prices firming and have entered into technical uptrends; Brazilian stocks bottomed and have entered uptrend, USD strength is reversing, etc. (I don't completely agree that fundamentals have no role in determining non-bear 10-20% corrections--1997, 1998 and 2011 had fundamental catalysts as did the Oct. 2014 dip.)

    Also, the market has been flattish YTD--historically, that is not a precursor to a seasonal correction--see 2004, 2005, 2006, 2007, 2014. Rather, it suggests that the next significant move is likely to be up rather than down. I'm not aware of a single correction in the past two decades that was preceded by a flattish market for several months (rather than a multi-month upward move)--think 1998, 2010, 2011, 2012 and Oct. 2014 corrections.

    Some of this chart monkey stuff (e.g. long-term trend channel) would in late 2012 have suggested a correction ahead. I think we could actually get a melt-up, led by industrial cyclicals and large-cap "value". But, I'm guessing the next big move is +8-10% rally on the S&P that carries through the end of the year and then continues into next spring.

    People like Julian Robertson and Druckenmiller have also noted recently the set-up for a melt-up. In fact, I believe the recent cautionary statements by Yellen and Fischer on stock prices represent a feeble attempt to "jaw-bone" down the market as they don't intend to raise rates this year and are worried the markets will "boil over" (i.e. melt-up) to use Robertson's colorful phrase.

    The only plausible trigger for a correction (outside of a Grexit, etc.) would be the upside growth surprises (that will come in due course this year) shocking the bond markets. Yet, the bond market tanked in mid-2013, and the stock correction was very minor and focused on bond proxy names, and was succeeded by a huge up move in stock prices. The first leg of a sharp bond correction has already started and has had no effect on stock prices. Stock multiples never really priced in the ultra-low long bond yield so still have quite a cushion in that sense.
    May 9, 2015. 07:22 PM | Likes Like |Link to Comment
  • Did Ben Graham Understand The Difference Between Active And Passive Investing? [View article]
    I consider many of the diversified "rules-based" funds and ETFs to be a form of indexing. Most people think of the S&P 500, but research has demonstrated that market-cap weighted indices provide sub-optimal performance as they overweight the more expensive stocks (and hot sectors) and underweight stocks and sectors that are out-of-favor and have asymmetric risk/reward to the upside. The late 1990s and 2000 market top would be an extreme example of this phenomenon. 2000 and 2001 were fantastic years, and the 2000s were not a lost decade at all, provided that you had a broad portfolio of reasonably valued stocks rather than the tech/pharma/financials... large-cap "growth"-oriented S&P 500.

    Value-weighted, sector-diversified funds such as the long-short funds run by Gotham Capital make a lot of sense, IMHO. Greenblatt magic formula long-only portfolios (value + quality), which could also be considered a form of indexing, have also been shown to consistently trounce the averages (and by definition, most active managers) over time. Research from AQR (Cliff Asness) supports this and also suggests that all Warren Buffett has really done historically was build reasonably diversified portfolios based on value with a tilt toward quality. He pick stocks, but it's not completely idiosyncratic--it's mostly value and quality factors--avoiding the garbage, and avoiding whatever is over-loved.

    So, I think indexing makes perfect sense, but not market-cap weighted indexing with no sector concentration caps and no value/quality tilt. The "quality" is particularly important in this era given all of the low ROIC, capital-destroying garbage floating around the markets these days, although much of that is in the Russell 2000.
    Apr 6, 2015. 01:40 AM | 2 Likes Like |Link to Comment
  • Celldex: An Immuno-Oncology Play With Monster Potential [View article]
    There's nothing wrong with that, but what will your total return be when the other 10 small-cap biotechs you bought 12 months ago crash and burn down 40-60% from where you bought them, and don't come back for many years (or never come back at all).

    If you're a brilliant enough biotech stock-picker that PCYC is the only one you bought, then more power to you.
    Apr 1, 2015. 02:17 PM | 2 Likes Like |Link to Comment
  • Celldex: An Immuno-Oncology Play With Monster Potential [View article]
    Your concerns sort of illustrate the point about whether any of us really has an "edge" when it comes to picking winners in this space--we are all the "fools at the poker table" compared to the players you mention especially in such a specialized, binary-event market such as early-stage biotech.
    Apr 1, 2015. 09:06 AM | Likes Like |Link to Comment
  • Celldex: An Immuno-Oncology Play With Monster Potential [View article]
    Fair enough on the 2008 reverse merger and pre-2008 share price history--I was not aware of that. And, I actually have no opinion one way or another on the merits of CLDX itself.

    The broader point though is that early-stage biotech is a percentages game with the percentages working against you when valuations are high given the huge number of flame-outs of once-promising companies.

    How do you know what's priced into the stock at the present time? It has a multi-billion dollar market cap and no significant revenue, so clearly, at least some portion of the pipeline and "potential" are already priced in.

    Historically, buying a basket of companies with multi-billion dollar market caps that are losing money and/or have no revenues consistently leads to one thing--big losses! Even if a couple of them work out in the end.
    Apr 1, 2015. 12:15 AM | 1 Like Like |Link to Comment
  • Celldex: An Immuno-Oncology Play With Monster Potential [View article]
    Much of this discussion, like discussion about other hot small-mid cap biotech stocks, is focused on the stock itself rather than the space. The problem I see here is that we are all "the suckers at the poker table"--we are disadvantaged vis-à-vis big pharma/biotech acquirers and specialty shops like Baker Bros. when it comes to picking the small number of future winners (out of a huge pool of likely failures) in this space. People talk about XYZ being the next AMGN or DNA while ignoring the vast number of also-ran losers--this is classic survivorship bias.

    That's why valuation matters so much--you want to buy a basket of these when they're out-of-favor rather than after they've had a huge parabolic run and are white-hot. Otherwise, you're likely to get poor returns unless you're lucky enough to pick the few winners.

    Recent take-out winner PCYC is a great example of this. It's being acquired for around 255. If you had bought it around the height of the last biotech bubble in 2000, you would now have made, depending on timing, 3x-5x of your purchase price over a 15-yr period. Not bad. However, only a small number of these development-stage companies make it or are acquired--most end up being big wipe-outs for their investors. If you bought a basket of these types of companies in 2000, it's unlikely that a 300-500% return on a couple of them would make up for the dozens that went down 80-100% (not to mention your cost-of-capital / time value of money over 15 yrs). Note that even CLDX, while still in the game and hot lately, is still down 80% from 2000--and I'm sure it looked very promising in 2000.

    Alternatively, if you had bought PCYC during a period when biotech was out-of-favor (rather than when it was hot), you would have gains of as much as 200-300x over an even smaller number of years. This is likely more than adequate to offset the numerous losers and wipe-outs, and you would have a truly outstanding return.

    Price/valuation matters (it protects you from the numerous unknowable risks), and we're currently more like 2000 (if not higher) with development-stage biotech valuations.
    Mar 31, 2015. 07:32 PM | 1 Like Like |Link to Comment
  • Celldex: An Immuno-Oncology Play With Monster Potential [View article]
    OK, but it seems as though you're making the past 18 months of strong price action out to be a CLDX-specific story. Nearly all of the spec biotechs have surged around the same time. CLDX may or may not have great prospects, but that action tells me something else is at play.

    Also, on 2007-08 events, note that CLDX consistently declined for nearly 20 years prior to that point. What were the excuses during that 20 years?

    Maybe CLDX will be the next AMGN or DNA, but it's hard to believe that the many dozens of mid-cap biotechs following a similar price trajectory over the past 18 months will all blossom accordingly.
    Mar 31, 2015. 08:19 AM | 2 Likes Like |Link to Comment
  • Celldex: An Immuno-Oncology Play With Monster Potential [View article]
    Honest question: CLDX has been public for 25 years, and has been consistently destroying shareholder capital the entire time (the stock is in a steady 25-yr downtrend), with the stock price every 6-8 years punctuated by a short-lived burst of speculative enthusiasm that quickly burns itself out.

    What makes "this time different" with regard to CLDX considering how the other bursts of enthusiasm in the share price have ended?

    On a related note, if this is all about a sudden revolution in the prospects for the biotech industry over the past 18 months, why is it that speculative, small-cap cash-burning companies in a wide variety of industries suddenly all burst to life around the same time beginning in 2013? Is this just a wild coincidence, or is it evidence of a market mania / speculative bubble in the capital markets rather than some independent miraculous turn in the prospects for small-cap biotech companies? Did the science suddenly make a quantum leap 18 months ago? Were their prospects really that much poorer three years ago than they are now?
    Mar 30, 2015. 11:40 PM | 1 Like Like |Link to Comment
  • A Buyback Or Biotech Bubble? [View article]
    The problem is that most of the biotechs in the XBI don't have any meaningful revenue / profits so pricing power isn't really the dynamic at play. What's in play are loose financial conditions (they enable cap-markets-driven roll-up acquisitions at outrageous prices by the likes of Valeant, Endo, Abb-vie, etc. as well as secondary offerings by the biotechs themselves) and a speculative, risk-embracing market mood that awards sky-high valuations based on "hope" and perceived growth potential and/or takeover possibility.

    If we get a deflationary collapse, the cap markets will collapse and so will anything that is "hot", speculative and trading at high valuations (including most biotechs).

    Even for the larger, profitable biotechs, I would be careful in assuming that they have firm pricing power--note the recent concerns with Gilead's Hep C drugs--pricing power by large buyers and competition from other biotechs.
    Mar 28, 2015. 06:45 PM | 3 Likes Like |Link to Comment
  • A Buyback Or Biotech Bubble? [View article]
    "Over the next decade, maybe, but not over the next three years"

    This indicates that you're speculating rather than investing. That's fine, but don't try to pass this off as "investment" advice.
    Mar 28, 2015. 06:38 PM | 1 Like Like |Link to Comment
  • A Buyback Or Biotech Bubble? [View article]

    XBI is all small and mid-cap biotechs which are most assuredly in a speculative bubble. Take a look at the long-term (25-year) chart of recent mo-mo fave CLDX. Consistent downward trend (i.e. capital destruction) punctuated by a speculative mania every 6-8 years that enables the company to do secondary share offerings at high prices to stay alive. Yes, there will be a couple of gems in the haystack that manage to do well long-term (just like internet stocks in 1999), but on average, investors in the space will do poorly from current valuations. Why do you think they've all been rushing to do secondary offerings recently?

    The non-takeover bait large-caps like GILD, Biogen and AMGN are not so frothy--the rest of the space is very frothy. In a way, this reflects the broader market where the S&P mega-caps are rich but not outrageously so, while the median stock valuation is much higher, and the Russell 2000 is at all-time high valuations.

    Also, Leo, "know thyself"--you're on record as having loved Nortel in 1999 and commodity stocks / rare earths in late 2011 and early 2012. That suggest you have an affinity / bias toward things that are coming off of multi-year bull markets and are primed for devastating losses. Think about it.
    Mar 28, 2015. 06:31 PM | 2 Likes Like |Link to Comment
  • XBI Is +24.22% YTD And +44.70% For 2014, But What Are The Risks? [View article]
    Small-cap biotech is in a speculative bubble the latest round of which has been driven by takeover speculation after the PCYC and Salix takeovers. Haven't you noticed all of the companies doing secondary share offerings over the past month to take advantage of these bubble prices? How about the CEO of momentum-fave PTCT dumping 100% of his holdings recently?

    If you want to take a look at how small-cap biotech trades over time, pull up the 30-yr chart of recent mo-mo fave CLDX. Basically, most of them destroy capital over time though every 8-10 yrs, the action is punctuated by a parabolic speculative bubble that subsequently collapses to lower lows. Yes, there may be a couple gems in the haystack, but on the whole, the space is a loser from these elevated valuations. I would avoid (or short, if you're brave) XBI.
    Mar 25, 2015. 04:14 PM | Likes Like |Link to Comment